Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement

Stephen Bagley(University of Pennsylvania), Shawn Kothari(University of Pennsylvania), Rifaquat Rahman(Dana-Farber Brigham Cancer Center), Eudocia Q. Lee(Center for Neuro-Oncology), Gavin P. Dunn(Washington University in St. Louis), Evanthia Galanis(Mayo Clinic), Susan M. Chang(University of California, San Francisco), Burt Nabors(University of Alabama at Birmingham), Manmeet S. Ahluwalia(Baptist Hospital of Miami), Roger Stupp(Northwestern University), Minesh P. Mehta(Baptist Hospital of Miami), David A. Reardon(Center for Neuro-Oncology), Stuart A. Grossman(Sidney Kimmel Cancer Center), Erik P. Sulman(New York University), John H. Sampson(Pediatric Brain Tumor Foundation), Simon Khagi(University of North Carolina at Chapel Hill), Michael Weller(University Hospital of Zurich), Timothy F. Cloughesy(University of California, Los Angeles), Patrick Y. Wen(Center for Neuro-Oncology), Mustafa Khasraw(Pediatric Brain Tumor Foundation)
Clinical Cancer Research
September 24, 2021
10.1158/1078-0432.ccr-21-2750
Cited by 161Open Access
Full Text

Abstract

Therapeutic advances for glioblastoma have been minimal over the past 2 decades. In light of the multitude of recent phase III trials that have failed to meet their primary endpoints following promising preclinical and early-phase programs, a Society for Neuro-Oncology Think Tank was held in November 2020 to prioritize areas for improvement in the conduct of glioblastoma clinical trials. Here, we review the literature, identify challenges related to clinical trial eligibility criteria and trial design in glioblastoma, and provide recommendations from the Think Tank. In addition, we provide a data-driven context with which to frame this discussion by analyzing key study design features of adult glioblastoma clinical trials listed on ClinicalTrials.gov as "recruiting" or "not yet recruiting" as of February 2021.

Related Papers

No related papers found

Powered by citation graph analysis